Citation Impact
Citing Papers
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Elective cyclosporine withdrawal after renal transplantation. A meta-analysis.
1993
Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients
2016
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients
2010
Pretransplant Immediately Early-1-Specific T Cell Responses Provide Protection for CMV Infection After Kidney Transplantation
2013
Antiviral drugs for cytomegalovirus diseases
2006
Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
2010
Nocardiosis: Updates and Clinical Overview
2012 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Prophylaxis Followed by Preemptive Therapy Versus Preemptive Therapy for Prevention of Human Cytomegalovirus Disease in Pediatric Patients Undergoing Liver Transplantation
2008
Use of Leflunomide in Renal Transplant Recipients with Ganciclovir-Resistant/Refractory Cytomegalovirus Infection: A Case Series from the University of Chicago
2015
Nocardiosis: Updated Clinical Review and Experience at a Tertiary Center
2010 Standout
Cytomegalovirus and Lung Transplantation
2004
Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation
2007
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
2013 Standout
Severe Sepsis and Septic Shock
2013 Standout
CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor
2017
Management of pediatric postrenal transplantation infections
2001
Pre-emptive Treatment for Cytomegalovirus Viremia to Prevent Cytomegalovirus Disease in Solid Organ Transplant Recipients
2006
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
2005
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Universal Prophylaxis or Preemptive Strategy for Cytomegalovirus Disease After Liver Transplantation: A Systematic Review and Meta-Analysis
2014
Nocardiosis at the Turn of the Century
2009 Standout
Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study
2007 Standout
Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial
2008
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
2008
Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences
2008
A Universal Preemptive Therapy for Cytomegalovirus Infections in Children After Live-Donor Liver Transplantation
2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Systematic Review and Meta-analysis
2008 Standout
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
2018 Standout
Long-Term Outcomes of Pre-emptive Valganciclovir Compared with Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation
2012
Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor–Based Immunosuppression? A Systematic Review and Meta-Analysis
2012
Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients
2012
Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients
2013
Infection in Solid-Organ Transplant Recipients
2007 Standout
A Hybrid Strategy for the Prevention of Cytomegalovirus-Related Complications in Pediatric Liver Transplantation Recipients
2009
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes
2016 StandoutNobel
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial
2011
Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term Outcomes
2009
Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients
2008
Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
2017
Clinical practice guidelines for antimicrobial prophylaxis in surgery
2013 Standout
Valganciclovir Dosing According to Body Surface Area and Renal Function in Pediatric Solid Organ Transplant Recipients
2009
Lost in publication: Half of all renal practice evidence is published in non-renal journals
2006
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
2013
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Evaluating non-randomised intervention studies
2003 Standout
Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study
2010
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
2011 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects*
1998
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
2000 Standout
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
2020 StandoutNobel
Intragraft Cytomegalovirus Infection: A Randomized Trial of Valacyclovir Prophylaxis versus Pre-Emptive Therapy in Renal Transplant Recipients
2010
Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: Long-term follow-up and study of metabolic consequences
2001
Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
2007
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
2013
Works of Peter Barclay being referenced
Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection
1998
Evaluation of the off‐label usage of rituximab in a large teaching hospital in New South Wales
2007
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials
2005
Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
1993
Costs of immunosuppressive therapies used in renal transplantation.
1992